X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs TEVA PHARMA (Israel) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   TEVA PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
TEVA PHARMA
Dec-13
LUPIN LTD/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4653,029-   
Low Rs7272,631-   
Sales per share (Unadj.) Rs349.61,738.2-  
Earnings per share (Unadj.) Rs5.6108.6-  
Cash flow per share (Unadj.) Rs29.6249.1-  
Dividends per share (Unadj.) Rs5.0095.05-  
Dividend yield (eoy) %0.53.4 13.6%  
Book value per share (Unadj.) Rs300.31,930.8-  
Shares outstanding (eoy) m452.08848.00-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.11.6 192.6%   
Avg P/E ratio x197.226.1 756.7%  
P/CF ratio (eoy) x37.111.4 326.2%  
Price / Book Value ratio x3.61.5 249.0%  
Dividend payout %90.087.5 102.8%   
Avg Mkt Cap Rs m495,5022,399,704 20.6%   
No. of employees `00017.044.9 37.9%   
Total wages/salary Rs m28,6470-   
Avg. sales/employee Rs Th9,273.632,795.3 28.3%   
Avg. wages/employee Rs Th1,681.00-   
Avg. net profit/employee Rs Th147.42,048.7 7.2%   
INCOME DATA
Net Sales Rs m158,0421,473,984 10.7%  
Other income Rs m1,5040-   
Total revenues Rs m159,5451,473,984 10.8%   
Gross profit Rs m31,475403,651 7.8%  
Depreciation Rs m10,859119,144 9.1%   
Interest Rs m2,04428,951 7.1%   
Profit before tax Rs m20,076255,556 7.9%   
Minority Interest Rs m-711,161 -6.1%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-167,759 8.7%   
Tax Rs m2,885-3,120 -92.5%   
Profit after tax Rs m2,51392,079 2.7%  
Gross profit margin %19.927.4 72.7%  
Effective tax rate %14.4-1.2 -1,176.8%   
Net profit margin %1.66.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m122,095995,523 12.3%   
Current liabilities Rs m50,956868,180 5.9%   
Net working cap to sales %45.08.6 521.0%  
Current ratio x2.41.1 209.0%  
Inventory Days Days8591 93.2%  
Debtors Days Days12096 125.0%  
Net fixed assets Rs m129,876481,436 27.0%   
Share capital Rs m9043,628 24.9%   
"Free" reserves Rs m134,8660-   
Net worth Rs m135,7711,637,316 8.3%   
Long term debt Rs m64,245753,681 8.5%   
Total assets Rs m263,0543,368,525 7.8%  
Interest coverage x10.89.8 110.2%   
Debt to equity ratio x0.50.5 102.8%  
Sales to assets ratio x0.60.4 137.3%   
Return on assets %1.73.6 48.2%  
Return on equity %1.95.6 32.9%  
Return on capital %3.74.9 75.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,8070-   
CASH FLOW
From Operations Rs m17,512234,877 7.5%  
From Investments Rs m-14,073-83,226 16.9%  
From Financial Activity Rs m-14,921-281,750 5.3%  
Net Cashflow Rs m-11,482-130,100 8.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare LUPIN LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare LUPIN LTD With: STRIDES PHARMA SCIENCE  J.B.CHEMICALS  MERCK LTD  NOVARTIS  SUN PHARMA  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Nov 13, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS